Cinda Biopharmaceutical, a startup that focuses on treating autoimmune and metabolic diseases, has recently announced the completion of its Phase I clinical study of human epidermal growth factor receptor-2 (HER2) and antibodies against programmed death receptor 1 (PD-1) in China.

According to reliable sources, Cinda had partnered with Hanmi Pharmaceutical to commence this study which focuses on evaluating the results of IBI315, a recombinant fully human IgG1 type anti-PD-1 / HER2 bispecific antibody, on patients with advanced solid malignant tumors along with HER2 expression.

The trial was targeted towards finding the effects of the drug when combined with chemotherapy and when used as a single-agent on advanced solid malignant tumors. It would further test the tolerability, safety and antitumor activity of the drug for Phase II studies in subjects.

Commenting on the progress, Dr. Zhou Hui, Vice President of Medical Science and Strategic Oncology, Cinda Biopharma, said that IBI315 would be the first-ever PD-1 / HER2 bispecific antibody which has managed to get into the clinical development stage. IBI315 is a significant part of Cinda's product portfolio for anti-tumor. Hence, developing this drug would create a substantial clinical value.

Hui added that the company hopes that IBI315 could fulfill the needs of those patients who are searching for a new and effective treatment option. It also hopes to solve major clinical needs while benefiting more patients.

Reportedly, Cinda Biopharmaceutical has also made some significant financial developments lately. In October 2019, the company revealed that it has agreed to place 97,000,000 new shares at HK $24.60 per share.

Sources close to the development claim that this new share offering would accelerate the development of other primary products in the company’s product range that wasn’t earlier disclosed in the original IPO prospectus.
 

Source Credit: http://innoventbio.com/#/news/179